Buy this shirt: https://apparelaholic.com/product/zach-edey-is-national-player-of-the-year-of-purdue-basketball-shirt/
So the Zach edey is national player of the year of purdue basketball shirt it is in the first place but question is: How do we bridge the gap? There are a lot of arguments that this is an intellectual-property issue. As Ryan Cooper points out in The Week, “rich countries have so far blocked efforts from poorer ones to get I.P. waivers through the World Trade Organization so that anybody with the equipment could manufacture the vaccines.” The idea is that that would free up the (admittedly small ) number of pharma companies that are not already producing vaccines to do so.
But the Zach edey is national player of the year of purdue basketball shirt it is in the first place but patent issue may not be the only answer. “The biggest problem is the technical know-how,” says Peter Hotez, dean of the National School of Tropical Medicine and professor of pediatrics and molecular virology and microbiology at Baylor College of Medicine. “Right now,” Hotez says, “there are no vaccines being manufactured in Africa and very few made in South and Central America. That really has not a lot to do with patents and more to do with human capital.” As Hotez explains it, “even if you liberalize the patents tomorrow, it won’t solve the problem quickly enough.” We need more “low-cost non-fussy vaccines” and the infrastructure to produce them. Hotez is working on a recombinant-protein vaccine that could be used in poor countries. “My dream would be to see the Biden administration finance four or five billion doses,” he adds.
Comentarios